The latest cancer drugs news
Browsing: Cancer Drug News
Common prostate cancer medications may be less safe than previously thought
Men taking either of the two most common oral medications for advanced prostate cancer who…
Ribociclib offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients
Novartis today announced updated median overall survival (OS) results for ribociclib in combination with fulvestrant…
Stem cell therapy protects against the side effects of cancer drugs
Immune checkpoint inhibitors are widely used to treat a variety of cancers; however, one serious…
Drugs showing promise in cancer trials reduce scarring for scleroderma
Epigenetic drugs that have shown promise in cancer trials significantly reduce scarring in the cells…
Tislelizumab plus chemo improved overall survival as first-line treatment for advanced oesophageal cancer in phase III study
Results from an interim analysis of the phase III RATIONALE 306 study, showed anti-PD-1 immune…
Protected: PBS listing for BRAFTOVI® (encorafenib) + cetuximab for metastatic colorectal (bowel) cancer patients with a BRAFV600 mutation(1)
This content is password-protected. To view it, please enter the password below. Password:
NICE reverses recommendation allowing use of novel urothelial carcinoma immunotherapy on the NHS
Merck and Pfizer have announced that, following a successful appeal of the prior Final Appraisal…
FDA approves lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer
The Food and Drug Administration have approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for the…
FDA approves nivolumab and relatlimab-rmbw for unresectable or metastatic melanoma
On March 18, 2022, the Food and Drug Administration approved nivolumab and relatlimab-rmbw for adult and…
ICR welcomes OlympiA trial showing targeted drug improves survival in early-stage breast cancer with inherited BRCA1 or BRCA2 mutation
The Institute of Cancer Research, London, UK, strongly welcomes new findings that the targeted drug…